Does evidence exist to include dietary therapy in the treatment of Crohn’s disease?

References

• Mayberry JF, Rhodes J. Epidemiological aspects of Crohn’s disease: a review of the literature. Gut25(8), 886–899 (1984).
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn’s disease: fact or fantasy? J. Pediatr.136(3), 285–291 (2000).
   PubMed Web of Science ®Google Scholar
• Sleisenger MH, Terdiman JP, Conrad PG. Genetic testing in hereditary colorectal cancer: indications and procedures. Am. J. Gastroenterol.94(9), 2344–2356 (1999).
   PubMedGoogle Scholar
• Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J. Clin. Immunol.20(5), 362–370 (2000).
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol.19(Suppl. A), 5–36 (2005).
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet369(9573), 1627–1640 (2007).
   PubMed Web of Science ®Google Scholar
• Appleyard CB, Hernández G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm. Bowel Dis.10(2), 106–111 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta N, Bostrom AG, Kirschner BS et al. Gender differences in presentation and course of disease in pediatric patients with Crohn’s disease. Pediatrics120(6), e1418–e1425 (2007).
   Google Scholar
• Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm. Bowel Dis.15(5), 734–741 (2009).
   PubMedGoogle Scholar
• García-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn’s disease. Behav. Res. Ther.42(4), 367–383 (2004).
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Familial clustering of Crohn’s disease in Israel: prevalence and association with disease severity. Inflamm. Bowel Dis.15(2), 171–175 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenic J. The risk of developing Crohn’s disease after an appendectomy: a meta-analysis. Am. J. Gastroenterol.103(11), 2925–2931 (2008).
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Peters TJ. Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview. Gut30, 22–28 (1989).
   PubMed Web of Science ®Google Scholar
• Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract. Res. Clin. Gastroenterol.18(3), 497–508 (2004).
   PubMedGoogle Scholar
• Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr. Opin. Gastroenterol.25(4), 329–333 (2009).
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol.12(30), 4807–4812 (2006).
   PubMed Web of Science ®Google Scholar
• Lochs H, Dejong C, Hammarqvist F et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin. Nutr.25, 260–274 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory bowel disease – epidemiology and treatment. Aliment Pharmacol. Ther.30(2), 99–112 (2009).
   PubMed Web of Science ®Google Scholar
• de Jong NS, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig. Dis. Sci.52(9), 2029–2036 (2007).
   PubMedGoogle Scholar
• Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.3, CD000542 (2007).
   Google Scholar
• Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM. Enteral nutrition in adult Crohn’s disease: present status and perspectives. Mol. Nutr. Food Res.52(8), 875–884 (2008).
   PubMedGoogle Scholar
• Akobeng AK, Richmond K, Miller V et al. Effect of exclusive enteral nutritional treatment on plasma antioxidant concentrations in childhood Crohn’s disease. Clin. Nutr.26(1), 51–56 (2007).
   PubMedGoogle Scholar
• Yamamoto T, Nakahigashi M, Umegae S et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment. Pharmacol. Ther.25(1), 67–72 (2007).
   PubMed Web of Science ®Google Scholar
• Takagi S, Utsunomiya K, Kuriyama S et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment. Pharmacol. Ther.24(9), 1333–1340 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson T, Macdonald S, Hill SM et al. Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut55(3), 356–361 (2006).
   PubMed Web of Science ®Google Scholar
• Eivindson M, Grønbaek H, Nielsen JN et al. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn’s disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand. J. Gastroenterol.40(10), 1214–1221 (2005).
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Iida M, Kohgo Y et al. Therapeutic efficacy of infliximab on active Crohn’s disease under nutritional therapy. Scand. J. Gastroenterol.40(12), 1423–1430 (2005).
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Krantz M, Bodin L et al. Elemental versus polymeric enteral nutrition in paediatric Crohn’s disease: a multicentre randomized controlled trial. Acta Paediatr.93(3), 327–335 (2004).
   PubMedGoogle Scholar
• Bamba T, Shimoyama T, Sasaki M et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur. J. Gastroenterol. Hepatol.15(2), 151–157 (2003).
   PubMedGoogle Scholar
• Gassull MA, Fernández-Bañares F, Cabré E et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut51(2), 164–168 (2002).
   PubMed Web of Science ®Google Scholar
• Sakurai T, Matsui T, Yao T et al. Short-term efficacy of enteral nutrition in the treatment of active Crohn’s disease: a randomized, controlled trial comparing nutrient formulas. JPEN J. Parenter. Enteral. Nutr.26(2), 98–103 (2002).
   PubMed Web of Science ®Google Scholar
• Verma S, Holdsworth CD, Giaffer MH. Does adjuvant nutritional support diminish steroid dependency in Crohn disease? Scand. J. Gastroenterol.36(4), 383–388 (2001).
   PubMed Web of Science ®Google Scholar
• Verma S, Kirkwood B, Brown S et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig. Liver Dis.32(9), 769–774 (2000).
   PubMedGoogle Scholar
• Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment. Pharmacol. Ther.14(3), 281–289 (2000).
   PubMed Web of Science ®Google Scholar
• Verma S, Brown S, Kirkwood B et al. Polymeric versus elemental diet as primary treatment in active Crohn’s disease: a randomized, double-blind trial. Am. J. Gastroenterol.95(3), 735–739 (2000).
   PubMed Web of Science ®Google Scholar
• Khoshoo V, Reifen R, Neuman MG et al. Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn‘s disease. JPEN J. Parenter. Enteral. Nutr.20(6), 401–405 (1996).
   PubMedGoogle Scholar
• Fukuda Y, Kosaka T, Okui M et al. Efficacy of nutritional therapy for active Crohn’s disease. J. Gastroenterol.30(Suppl. 8), 83–87 (1995).
   PubMedGoogle Scholar
• Breese EJ, Michie CA, Nicholls SW et al. The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment. Pharmacol. Ther.9(5), 547–552 (1995).
   PubMedGoogle Scholar
• Israel DM, Hassall E. Prolonged use of gastrostomy for enteral hyperalimentation in children with Crohn’s disease. Am. J. Gastroenterol.90(7), 1084–1088 (1995).
   PubMedGoogle Scholar
• Royall D, Greenberg GR, Allard JP et al. Total enteral nutrition support improves body composition of patients with active Crohn’s disease. JPEN J. Parenter. Enteral. Nutr.19(2), 95–99 (1995).
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn’s disease. Gut36(1), 60–66 (1995).
   PubMed Web of Science ®Google Scholar
• Ruuska T, Savilahti E, Mäki M et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn’s disease in children. J. Pediatr. Gastroenterol. Nutr.19(2), 175–180 (1994).
   PubMed Web of Science ®Google Scholar
• Royall D, Jeejeebhoy KN, Baker JP et al. Comparison of amino acid V peptide based enteral diets in active Crohn’s disease: clinical and nutritional outcome. Gut35(6), 783–787 (1994).
   PubMedGoogle Scholar
• González-Huix F, de León R, Fernández-Bañares F et al. Polymeric enteral diets as primary treatment of active Crohn’s disease: a prospective steroid controlled trial. Gut34(6), 778–782 (1993).
   PubMed Web of Science ®Google Scholar
• Hirakawa H, Fukuda Y, Tanida N et al. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn’s disease. Gastroenterol. Jpn28(3), 379–384 (1993).
   PubMedGoogle Scholar
• Rigaud D, Cosnes J, Le Quintrec Y et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn’s disease: elemental versus polymeric diet. Gut32(12), 1492–1497 (1991).
   PubMed Web of Science ®Google Scholar
• Demetriou AA. Comparison of enteral nutrition and drug treatment in active Crohn’s disease: results of the European Cooperative Crohn’s Disease Study IV. JPEN J. Parenter. Enteral. Nutr.16(1), 84–85 (1992).
   PubMedGoogle Scholar
• Abad-Lacruz A, González-Huix F, Esteve M et al. Liver function tests abnormalities in patients with inflammatory bowel disease receiving artificial nutrition: a prospective randomized study of total enteral nutrition vs total parenteral nutrition. JPEN J. Parenter. Enteral. Nutr.14(6), 618–621 (1990).
   PubMed Web of Science ®Google Scholar
• Giaffer MH, North G, Holdsworth CD. Controlled trial of polymeric versus elemental diet in treatment of active Crohn’s disease. Lancet335(8693), 816–819 (1990).
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Fleming CR, Jeejeebhoy KN et al. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut29(10), 1309–1315 (1988).
   PubMed Web of Science ®Google Scholar
• Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology94(3), 603–610 (1988).
   PubMed Web of Science ®Google Scholar
• Akobeng AI, Clayton PE, Miller V et al. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine supplementation. Scand. J. Gastroenterol.37(12), 1422–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Miller V, Stanton J et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.30(1), 78–84 (2000).
   PubMed Web of Science ®Google Scholar
• Schneeweiss B, Lochs H, Zauner C et al. Energy and substrate metabolism in patients with active Crohn’s disease. J. Nutr.129(4), 844–848 (1999).
   PubMedGoogle Scholar
• Stolk MF, Van Erpecum KJ, Hiemstra G et al. Gallbladder motility and cholecystokinin release during long-term enteral nutrition in patients with Crohn’s disease. Scand. J. Gastroenterol.29(10), 934–939 (1994).
   PubMed Web of Science ®Google Scholar
• Lochs H, Steinhardt HJ, Klaus-Wentz B, Zeitz M et al. Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Results of the European Cooperative Crohn’s Disease Study. IV. Gastroenterology101(4), 881–888 (1991).
   PubMed Web of Science ®Google Scholar
• Matsui T, Sakurai T, Yao T. Nutritional therapy for Crohn’s disease in Japan. J. Gastroenterol.40(Suppl. 16), 25–31 (2005).
   PubMedGoogle Scholar
• Axelsson C, Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand. J. Gastroenterol.12(1), 89–95 (1977).
   PubMed Web of Science ®Google Scholar
• Göschke H, Buess H, Gyr K et al. [Elementary diet as an alternative to parenteral feeding in severe gastrointestinal diseases.] Schweiz. Med. Wochenschr.107(2), 43–49 (1977).
   PubMedGoogle Scholar
• O’Morain C. Elemental diets in the treatment of Crohn’s disease. Proc. Nutr. Soc.38, 403 (1979).
   PubMedGoogle Scholar
• Yamamoto T, Nakahigashi M, Saniabadi AR et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm. Bowel Dis.13(12), 1493–1501 (2007).
   PubMed Web of Science ®Google Scholar
• Rowe AH, Rowe A Jr, Uyeyama K. Regional enteritis; its allergic aspects. Gastroenterology23(4), 554–571 (1953).
   PubMedGoogle Scholar
• Vaisman N, Dotan I, Halack A, Niv E. Malabsorption is a major contributor to underweight in Crohn’s disease patients in remission. Nutrition22(9), 855–859 (2006).
   PubMedGoogle Scholar
• Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm. Bowel Dis.16(1), 137–151 (2010).
   PubMed Web of Science ®Google Scholar
• Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J. Gastroenterol.15(21), 2570–2578 (2009).
   PubMed Web of Science ®Google Scholar
• Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr. Opin. Gastroenterol.23(4), 400–405 (2007).
   PubMed Web of Science ®Google Scholar
• Rigaud D, Cerf M, Angel Alberto L, Sobhani I, Carduner MJ, Mignon M. [Increase of resting energy expenditure during flare-ups in Crohn disease.] Gastroenterol. Clin. Biol.17(12), 932–937 (1993).
   PubMedGoogle Scholar
• Heyman MB, Garnett EA, Wojcicki J et al. Growth hormone treatment for growth failure in pediatric patients with Crohn’s disease. J. Pediatr.153(5), 651–658, (2008).
   PubMedGoogle Scholar
• Finn R. Food allergy – fact or fiction: a review. J. R. Soc. Med.85(9), 560–564 (1992).
   PubMedGoogle Scholar
• Lack G. Clinical practice. Food allergy. N. Engl. J. Med.359(12), 1252–1260 (2008).
   PubMed Web of Science ®Google Scholar
• Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO. Crohn’s disease: maintenance of remission by diet. Lancet2(8448), 177–180 (1985).
   PubMed Web of Science ®Google Scholar
• Giaffer MH, Cann P, Holdsworth CD. Long-term effects of elemental and exclusion diets for Crohn’s disease. Aliment. Pharmacol. Ther.5(2), 115–125 (1991).
   PubMedGoogle Scholar
• Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn’s disease. Gut34(6), 783–787 (1993).
   PubMed Web of Science ®Google Scholar
• Workman EM, Alun Jones V, Wilson AJ et al. Diet in the management of Crohn’s disease. Hum. Nutr. Appl. Nutr.38(6), 469–473 (1984).
   PubMedGoogle Scholar
• Ballegaard M, Bjergstrøm A, Brøndum S et al. Self-reported food intolerance in chronic inflammatory bowel disease. Scand. J. Gastroenterol.32(6), 569–571 (1997).
   PubMed Web of Science ®Google Scholar
• Joneja JV. Dealing with Food Allergies. Bull Publishing Company, CO, USA (2003).
   Google Scholar
• Bischoff SC, Mayer JH, Manns MP. Allergy and the gut. Int. Arch. Allergy Immunol.121(4), 270–283 (2000).
   PubMed Web of Science ®Google Scholar
• Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn’s disease. Long-term maintenance of remission by personalized food exclusion diets. Dig. Dis. Sci.32(12 Suppl.), S100–S107 (1987).
   Web of Science ®Google Scholar
• Stange EF, Schmid U, Fleig WE, Ditschuneit H. Exclusion diet in Crohn disease: a controlled, randomized study. Z. Gastroenterol.28(10), 561–564 (1990).
   PubMedGoogle Scholar
• Riordan AM, Rucker JT, Kirby GA, Hunter JO. Food intolerance and Crohn’s disease. Gut35(4), 571–572 (1994).
   PubMedGoogle Scholar
• Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn’s disease. J. Pediatr. Gastroenterol. Nutr.17(1), 75–81 (1993).
   PubMed Web of Science ®Google Scholar
• Ferguson MM, MacFadyen EE. Orofacial granulomatosis – a 10 year review. Ann. Acad. Med. Singapore15(3), 370–377 (1986).
   PubMedGoogle Scholar
• Kajosaari M. Food allergy in Finnish children aged 1 to 6 years. Acta Paediatr. Scand.71(5), 815–819 (1982).
   PubMed Web of Science ®Google Scholar
• Walker WA. Allergen absorption in the intestine: implication for food allergy in infants. J. Allergy Clin. Immunol.78, 1003–1009 (1986).
   PubMed Web of Science ®Google Scholar
• Green TJ, Issenman RM, Jacobson K. Patients’ diets and preferences in a pediatric population with inflammatory bowel disease. Can. J. Gastroenterol.12(8), 544–549 (1998).
   PubMedGoogle Scholar
• Simpson JW. Diet and large intestinal disease in dogs and cats. J. Nutr.128(12 Suppl.), S2717–S2722 (1998).
   PubMed Web of Science ®Google Scholar
• Guilford WG. Nutritional management of gastrointestinal tract diseases of dogs and cats. J. Nutr.124(12 Suppl.), S2663–S2669 (1994).
   Google Scholar
• Forbes A. Review article: Crohn’s disease – the role of nutritional therapy. Aliment. Pharmacol. Ther.16(Suppl. 4), 48–52 (2002).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Iwao Y, Okamoto S, Ogata H, Hibi T, Kazuma K. Coping strategy when patients with quiescent Crohn’s disease recognize that their conditions are worsening. J. Gastroenterol.44(11), 1109–1112 (2009).
   PubMedGoogle Scholar
• Niewinski MM. Advances in celiac disease and gluten-free diet. J. Am. Diet. Assoc.108(4), 661–672 (2008).
   PubMed Web of Science ®Google Scholar
• Joachim G. Responses of people with inflammatory bowel disease to foods consumed. Gastroenterol. Nurs.23(4), 160–167 (2000).
   PubMedGoogle Scholar
• Mantzaris GJ, Roussos A, Koilakou S et al. Prevalence of celiac disease in patients with Crohn’s disease. Inflamm. Bowel Dis.11(11), 1029 (2005).
   PubMedGoogle Scholar
• Tursi A, Giorgetti GM, Brandimarte G, Elisei W. High prevalence of celiac disease among patients affected by Crohn’s disease. Inflamm. Bowel Dis.11(7), 662–666 (2005).
   PubMed Web of Science ®Google Scholar
• Leeds JS, Höroldt BS, Sidhu R et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand. J. Gastroenterol.42(10), 1214–1220 (2007).
   PubMed Web of Science ®Google Scholar
• A case of Crohn’s disease in a patient with treated adult coeliac disease; demonstrated at the Royal Postgraduate Medical School. Br. Med. J.4(5573), 222–226 (1967).
   PubMedGoogle Scholar
• Euler AR, Ament ME. Celiac sprue and Crohn’s disease: an association causing severe growth retardation. Gastroenterology72, 729–731 (1977).
   PubMedGoogle Scholar
• Gillberg R, Dotevall G, Ahrén C. Chronic inflammatory bowel disease in patients with coeliac disease. Scand. J. Gastroenterol.17(4), 491–496 (1982).
   PubMed Web of Science ®Google Scholar
• Bulger K, Griffin M, Dervan P, Lennon J, Crowe J. Coeliac disease in association with inflammatory bowel disease. Postgrad. Med. J.64(750), 336 (1988).
   PubMedGoogle Scholar
• Curtis WD, Schuman BM, Griffin JW Jr. Association of gluten-sensitive enteropathy and Crohn’s colitis. Am. J. Gastroenterol.87(11), 1634–1637 (1992).
   PubMedGoogle Scholar
• Karoui S, Boubaker J, Hamzaoui S, Be Yaghlene L, Filali A. [Association of asymptomatic celiac disease and Crohn’s disease.] Ann. Med. Interne (Paris)151(5), 411–412 (2000).
   PubMedGoogle Scholar
• Chakraborty A, Bremner AR, Moore I, Beattie RM. Coeliac disease and Crohn’s disease: an association not to be forgotten. Hosp. Med.64(11), 684–685 (2003).
   PubMed Web of Science ®Google Scholar
• Schedel J, Rockmann F, Bongartz T, Woenckhaus M, Scholmerich J, Kullmann F. Association of Crohn’s disease and latent celiac disease: a case report and review of the literature. Int. J. Colorectal. Dis.20(4), 376–380 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson CR, Cerda JJ. Dietary therapy in gastrointestinal disease. Compr. Ther.15(2), 62–65 (1989).
   PubMedGoogle Scholar
• Barta Z, Csípö I, Antal-Szalmás P, Sipka S, Szabo G, Szegedi G. [Anti-Saccharomyces cerevisiae antibodies in patients with Crohn’s disease.] Orv. Hetil.142(42), 2303–2307 (2001).
   PubMedGoogle Scholar
• Vernia P, Di Camillo M, Marinaro V. Lactose malabsorption, irritable bowel syndrome and self-reported milk intolerance. Dig. Liver Dis.33(3), 234–239 (2001).
   PubMedGoogle Scholar
• Ehrenpreis ED. Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis. Geriatrics60(1), 25–28 (2005).
   PubMedGoogle Scholar
• McBean LD, Miller GD. Allaying fears and fallacies about lactose intolerance. J. Am. Diet. Assoc.98(6), 671–676 (1998).
   PubMedGoogle Scholar
• Meryn S. Role of nutrition in acute and long-term therapy of chronic inflammatory bowel diseases. Wien. Klin. Wochenschr.98(22), 774–779 (1986).
   PubMedGoogle Scholar
• Bujanover Y, Katz A, Peled Y, Gilat T. Lactose malabsorption in Israeli children. Isr. J. Med. Sci.21(1), 32–35 (1985).
   PubMedGoogle Scholar
• von Tirpitz C, Kohn C, Steinkamp M et al. Lactose intolerance in active Crohn’s disease: clinical value of duodenal lactase analysis. J. Clin. Gastroenterol.34(1), 49–53 (2002).
   PubMed Web of Science ®Google Scholar
• Barrett JS, Irving PM, Shepherd SJ, Muir JG, Gibson PR. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment. Pharmacol. Ther.30(2), 165–174 (2009).
   PubMed Web of Science ®Google Scholar
• Lerner A, Rossi TM, Park B, Albini B, Lebenthal E. Serum antibodies to cow‘s milk proteins in pediatric inflammatory bowel disease. Crohn‘s disease versus ulcerative colitis. Acta Paediatr. Scand.78(3), 384–389 (1989).
   PubMed Web of Science ®Google Scholar
• Jewell DP, Truelove SC. Circulating antibodies to cow’s milk proteins in ulcerative colitis. Gut13(10), 796–801 (1972).
   PubMed Web of Science ®Google Scholar
• Gudmand-Høyer E. The clinical significance of disaccharide maldigestion. Am. J. Clin. Nutr.59(3 Suppl.), S735–S741 (1994).
   PubMedGoogle Scholar
• Ojetti V, Nucera G, Migneco A et al. High prevalence of celiac disease in patients with lactose intolerance. Digestion71(2), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Harrer M, Reinisch W, Dejaco C et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn’s disease? Eur. J. Gastroenterol. Hepatol.15(12), 1281–1285 (2003).
   PubMedGoogle Scholar
• Hollander D. Permeability in Crohn’s disease: altered barrier functions in healthy relatives? Gastroenterology104(6), 1848–1851 (1993).
   PubMed Web of Science ®Google Scholar
• Peeters M, Geypens B, Claus D et al. Clustering of increased small intestinal permeability in families with Crohn’s disease. Gastroenterology113(3), 802–807 (1997).
   PubMed Web of Science ®Google Scholar
• Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn’s disease patients at low risk for lactose malabsorption based on ethnic origin. Am. J. Gastroenterol.92(7), 1148–1153 (1997).
   PubMed Web of Science ®Google Scholar
• Banos G, Brotherstone S, Coffey MP. Evaluation of body condition score measured throughout lactation as an indicator of fertility in dairy cattle. J. Dairy Sci.87(8), 2669–2676 (2004).
   PubMedGoogle Scholar
• Gudmand-Hoyer E, Jarnum S. Incidence and clinical significance of lactose malabsorption in ulcerative colitis and Crohn’s disease. Gut11(4), 338–343 (1970).
   PubMed Web of Science ®Google Scholar
• Hass SV, Hass MP. Management of Celiac Disease. Lippincott, PA, USA (1951).
   Google Scholar
• Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn’s disease with an unrefined-carbohydrate, fibre-rich diet. Br. Med. J.2(6193), 764–766 (1979).
   PubMed Web of Science ®Google Scholar
• Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn’s disease. Br. Med. J. (Clin. Res. Ed.)295(6597), 517–520 (1987).
   PubMed Web of Science ®Google Scholar
• Brandes JW, Lorenz-Meyer H. Sugar free diet: a new perspective in the treatment of Crohn disease? Randomized, control study. Z. Gastroenterol.19(1), 1–12 (1981).
   PubMedGoogle Scholar
• Lorenz-Meyer H, Bauer P, Nicolay C et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn‘s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn‘s Disease Study Group). Scand. J. Gastroenterol.31(8), 778–785 (1996).
   PubMed Web of Science ®Google Scholar
• Nieves R, Jackson RT. Specific carbohydrate diet in treatment of inflammatory bowel disease. Tenn. Med.97(9), 407 (2004).
   PubMedGoogle Scholar
• Arnott ID, Landers CJ, Nimmo EJ et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol.99(12), 2376–2384 (2004).
   PubMed Web of Science ®Google Scholar
• Ashorn S, Honkanen T, Kolho KL et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis.15(2), 199–205 (2009).
   PubMed Web of Science ®Google Scholar
• Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford)47(2), 142–144 (2008).
   PubMed Web of Science ®Google Scholar
• Barclay GR, McKenzie H, Pennington J et al. The effect of dietary yeast on the activity of stable chronic Crohn’s disease. Scand. J. Gastroenterol.27(3), 196–200 (1992).
   PubMed Web of Science ®Google Scholar
• Desplat-Jégo S, Johanet C, Escande A et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J. Gastroenterol.13(16), 2312–2318 (2007).
   PubMed Web of Science ®Google Scholar
• Fresko I, Ugurlu S, Ozbakir F et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet’s syndrome. Clin. Exp. Rheumatol.23(4 Suppl. 38), S67–S70 (2005).
   PubMed Web of Science ®Google Scholar
• Kim BC, Park S, Han J et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn’s disease and its relationship to the disease clinical course. Dig. Liver Dis.39(7), 610–616 (2007).
   PubMedGoogle Scholar
• Lindberg E, Magnusson KE, Tysk C, Janerot G. Antibody (IgG, IgA, and IgM) to baker’s yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut33(7), 909–913 (1992).
   PubMed Web of Science ®Google Scholar
• Mallant-Hent RCh, Mary B, von Blomberg E et al. Disappearance of anti-Saccharomycescerevisiae antibodies in coeliac disease during a gluten-free diet. Eur. J. Gastroenterol. Hepatol.18(1), 75–78 (2006).
   PubMed Web of Science ®Google Scholar
• Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosis. Dig. Dis. Sci.52(1), 33–39 (2007).
   PubMed Web of Science ®Google Scholar
• Riis L, Vind I, Vermeire S et al.; European Collaborative Study Group on Inflammatory Bowel Disease. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm. Bowel Dis.13(1), 24–32 (2007).
   PubMed Web of Science ®Google Scholar
• Sutton CL, Yang H, Li Z, Rotter JI, Targen SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut46(1), 58–63 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fukuda Y, Koizuka H et al. Dietary antigens in Crohn’s disease: antibodies to porcine pancreatic amylase. Am. J. Gastroenterol.103(3), 656–664 (2008).
   PubMed Web of Science ®Google Scholar
• Oshitani N, Hato F, Matsumoto T et al. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn’s disease. J. Gastroenterol. Hepatol.15(12), 1400–1403 (2000).
   PubMed Web of Science ®Google Scholar
• Barahona-Garrido J, Sarti HM, Barahona-Garrido MK et al. Serological markers in inflammatory bowel disease: a review of their clinical utility. Rev. Gastroenterol. Mex.74(3), 230–237 (2009).
   PubMedGoogle Scholar
• Lichtenstein GR, Olson A, Travers S et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am. J. Gastroenterol.101(5), 1030–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut53(8), 1117–1122 (2004).
   PubMed Web of Science ®Google Scholar
• Van Den Bogaerde J, Cahill J, Emmanuel AV et al. Gut mucosal response to food antigens in Crohn’s disease. Aliment. Pharmacol. Ther.16(11), 1903–1915 (2002).
   PubMedGoogle Scholar
• Tragnone A, Valpiani D, Miglio F et al. Dietary habits as risk factors for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol.7(1), 47–51 (1995).
   PubMed Web of Science ®Google Scholar
• Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr.63(5), 741–745 (1996).
   PubMed Web of Science ®Google Scholar
• Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. Pre-illness dietary factors in inflammatory bowel disease. Gut40(6), 754–760 (1997).
   PubMedGoogle Scholar
• Nieuwenhuizen WF, Pieters RH, Knippels LM, Jansen MC, Koppelman SJ. Is Candida albicans a trigger in the onset of coeliac disease? Lancet361(9375), 2152–2154 (2003).
   PubMedGoogle Scholar
• Mpofu CM, Campbell BJ, Subramanian S et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn’s disease. Gastroenterology133(5), 1487–1498 (2007).
   PubMedGoogle Scholar
• Jawhara S, Thuru X, Standaert-Vitse A et al. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis.197(7), 972–980 (2008).
   PubMed Web of Science ®Google Scholar
• Benjamin J, Makharia GK, Joshi YK. Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn’s disease. Inflamm. Bowel Dis.14(11), 1610–1611 (2008).
   PubMedGoogle Scholar
• Cummings JH, Antoine JM, Azpiroz F et al. PASSCLAIM – gut health and immunity. Eur J Nutr.43(Suppl. 2), II118–II173 (2004).
   PubMed Web of Science ®Google Scholar
• Fasano A. Surprises from celiac disease. Sci. Am.301(2), 54–61 (2009).
   PubMed Web of Science ®Google Scholar
• Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn’s disease. Eur. J. Gastroenterol. Hepatol.13(2), 101–106 (2001).
   PubMed Web of Science ®Google Scholar
• Lomer MC, Grainger SL, Ede R et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn’s disease. Eur. J. Gastroenterol. Hepatol.17(3), 377–384 (2005).
   PubMed Web of Science ®Google Scholar
• Bartel G, Weiss I, Turetschek K, Schima W et al. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm. Bowel Dis.14(3), 374–382 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan SN. Hypothesis revisited: toothpaste and the cause of Crohn’s disease. Lancet336(8723), 1096–1097 (1990).
   PubMed Web of Science ®Google Scholar
• Chess S, Olander G, Puestow CB, Benner W, Chess D. Regional enteritis; clinical and experimental observations. Surg. Gynecol. Obstet.91(3), 343–350 (1950).
   PubMedGoogle Scholar
• Coffey RJ. Pathologic manifestations of regional enteritis. Mayo Clin. Proc.13, 541–544 (1938).
   Google Scholar
• Shepherd NA, Crocker PR, Smith AP, Levison DA. Exogenous pigment in Peyer’s patches. Hum. Pathol.18(1), 50–54 (1987).
   PubMedGoogle Scholar
• Powell JJ, Ainley CC, Harvey RS. Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Gut38(3), 390–395 (1996).
   PubMed Web of Science ®Google Scholar
• Powell JJ, Harvey RS, Ashwood P et al. Immune potentiation of ultrafine dietary particles in normal subjects and patients with inflammatory bowel disease. J. Autoimmun.14(1), 99–105 (2000).
   PubMed Web of Science ®Google Scholar
• Mahmud N, Weir DG. The urban diet and Crohn’s disease: is there a relationship? Eur. J. Gastroenterol. Hepatol.13(2), 93–95 (2001).
   PubMed Web of Science ®Google Scholar
• Van Gossum M, Mascart F, Rickaert F, Codden T, Colonius V. [Lactose and gluten intolerance: which to suscept?] Rev. Med. Brux.21(4), A303–A308 (2000).
   Google Scholar